Subscribe
lost-my-umbrella
20 November 2013Americas

Teva to lose grip on Copaxone next year

The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
US court rules Teva patent invalid
30 July 2013   A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
Americas
FDA approval adds new life to Copaxone
29 January 2014   On January 28, Teva announced that the FDA had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

article
US court rules Teva patent invalid
30 July 2013   A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
Americas
FDA approval adds new life to Copaxone
29 January 2014   On January 28, Teva announced that the FDA had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.

More on this story

article
US court rules Teva patent invalid
30 July 2013   A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
Americas
FDA approval adds new life to Copaxone
29 January 2014   On January 28, Teva announced that the FDA had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility